The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Januvia Ranked No.1 in GP Market in June: Anterio’s “Mind Share” Ranking
July 28, 2014
- TS-1 Fails to Meet Primary Endpoint in PIII Study in Japan for Advanced Hepatocellular Carcinoma: Taiho
July 28, 2014
- Chugai Half-Year Earnings Upbeat on Actemra; Anti-PCSK9 Drug Ditched from Pipeline
July 25, 2014
- Kyowa Kirin Launches PII Study for XLH Drug KRN23 in US, Europe
July 25, 2014
- Sumitomo Dainippon, Taiho to Invest US$30 Million Each in Remiges BioPharma Fund
July 25, 2014
- Ono, BMS Announce Strategic Alliance for 5 Immuno-Oncology Products
July 25, 2014
- R-Tech Ueno Files for Orphan Drug Designation for Unoprostone Isopropyl for Retinitis Pigmentosa
July 25, 2014
- With Series of Antidiabetics on the Way, Prioritization Will Be a Challenge: Lilly Japan Diabetes Head
July 25, 2014
- Astellas Gears Up to Accelerate R&D
July 24, 2014
- Maruho Seeks Approval of Antibacterial Drug Ozenoxacin in Japan
July 24, 2014
- Japan Antidepressant Market Valued at 151 Billion Yen in 2022
July 24, 2014
- Jiangsu Hengrui Medicine of China Establishes Japanese Subsidiary; Aims for Sales of 10 Billion Yen by 2022
July 24, 2014
- Takeda, ASKA to Cease Seltouch Marketing by Late September
July 24, 2014
- Kyorin Licenses OAB Treatment Vibegron from Merck
July 24, 2014
- Research Lab for High-Value Generics Goes Live: Kobayashi Kako
July 23, 2014
- Terumo US Unit Opens New Plant in Vietnam
July 23, 2014
- Tatsumi Kagaku Adjusts Supply of Nu-lotan Generic
July 22, 2014
- Disclosure of Payments from Drug Makers to Doctors Delayed
July 22, 2014
- Chugai Obtains Marketing Rights for Antiemetic NEPA in the UK, Ireland from Helsinn Group
July 22, 2014
- Ethical Drug Sales Down 6.5% in May: Crecon Report
July 18, 2014
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…